The Neuro4D Conference 2022
Drug Discovery for Proteopathic Neurodegenerative Diseases:
New Disease Models, Latest Technologies and Innovative Targets
CANCELLATION OF 2021 NEURO4D CONFERENCE DUE TO CONTINUED COVID19 RESTRICTIONS!
The Neuro4D is an international conference on Neuro Degenerative Disease Drug Discovery bringing together drug discovery companies, service and technology providers and academic innovators in the field of proteopathic neurodegenerative diseases in a highly interactive format.
The conference differentiates itself by bringing together distinguished industry and academic speakers specialized in neurodegenerative disease drug discovery. Biotech and international pharmaceutical drug discovery companies will present their most recent achievements to develop new treatment options and outline the models and technologies used in compound selection and optimization. Service and technology companies will present their platforms and show examples of how their services contribute to the discovery of new drug candidates.
Due to the Covid19 situation and connected travel and meeting restrictions, the Neuro4D Conference 2021 can not be held. In our view an online version makes no sense for this conference format, as the main benefit are direct personal contacts and lively collaborative discussions. Consequently we will wait until the vaccination and herd immunity will control disease spreading, likely after the summer of 2021! We will keep you informed of our planning for 2022 and hope that the great location we had identified for the 2020 event will still be available.
The 2022 conference will keep the successful session format and chairman lead control of the 2019 event. We are planning a full session on clinical translations of drug discovery programs, clinical trial designs and their limitations. We will have a session on Alzheimer’s and Parkinson’s disease and attempt to cover additional proteopathic neurodegenerative diseases.
The 2022 Neuro4D conference will be held in a new location in Mainz, originally selected for 2020. Registration will include conference room bookings from Monday to Tuesday for all delegates and includes all food and drinks during the entire event, joint social activities and the conference dinner at the end of the first day.
Call for Poster Abstracts:
Poster abstracts abstracts (max. 300 words) are requested before March 10th, 2022. They will be evaluated and selected by March 31st, 2022. Accepted abstracts of participating delegates will be published in the program. Submit Abstracts in MS Word, or as Email text to the organizer: firstname.lastname@example.org
Poster boards have a width of 118.5 cm and a height of 146 cm. Posters must have a maximum size of A0 (84 × 119 cm) and portrait orientation. Poster presenters need to be at their posters during dedicated breaks.
The Neuro4D Poster Award: ‚For the best approach against neurodegenerative diseases, presented at the International Neuro4D Conference 2022‘ will be selected by all conference participants and awarded with 1000 € in cash!
Presentations will be again 10 min. A chairman-led Q&A session of approximately 5 min and a 15 min session discussion will take place. If you are interested to give a presentation 2022, please contact the organizers.
- Topics Highlights:
- Parkinson’s disease session, co-organized and chaired by Tiago Outeiro.
- Alzheimer’s disease session, co-organized and chaired by Neil Cashman
- Translation to Clinical Trials, co-organized and chaired by Oliver Peters.
- New developments in other neurodegenerative diseases: ALS, ataxia & polyglutamine disorders
- New targets and drug candidates :
- Novel disease models and target validation technologies
- In vitro screening on targets
- In vitro validation in (human) neuronal models
- In vivo models and biomarkers
- Target Audience:
- Drug discovery experts from biotechs and the pharmaceutical industry
- Academic experts in proteopathic neurodegenerative diseases interested in drug discovery
- Service providers with novel models in neurodegeneration
- Pharma strategists and investors interested in the neurodegenerative field
- Advisory Committee:
Tiago Outeiro, University of Göttingen, Germany
Rakez Kayed, U. Texas, USA
Oliver Peters, Charité, Germany
Dr. Andreas Köpke (bioExpert)
Tel: +49 6136 957 3000